IamPsychiatry highlights ADHD treatment gap following adult diagnosis

For adults seeking support with Attention Deficit Hyperactivity Disorder, receiving a formal evaluation often marks only the beginning of a prolonged waiting period rather than a resolution. Private mental health services have drawn renewed attention to the critical treatment gap that follows an adult diagnosis, as patients must navigate complex hurdles before securing access to necessary medication and ongoing psychiatric care. This ongoing challenge in adult mental health provision coincides with broader systemic strain across the NHS, where rising referral volumes have severely impacted waiting lists and exposed deep regional disparities in care delivery.

The issue stems from a structural disconnect between diagnostic assessment and the separate clinical process required to establish a stable pharmaceutical treatment plan. According to findings highlighted by private clinic IamPsychiatry, establishing whether a patient meets diagnostic criteria is entirely distinct from managing medication titration. This clinical phase requires careful introduction and adjustment of pharmaceutical interventions while closely monitoring therapeutic effects, tolerability, and potential side effects over multiple reviews.

Context surrounding these delays connects directly to findings published by the NHS England ADHD Taskforce, which identified significant pressures across both diagnosis and treatment pathways. Referrals have risen substantially while waiting lists have grown. A summary report indicated that only an estimated fraction of adults with ADHD receive medication, pointing to wide geographic variation in prescribing practices and access to comprehensive ongoing services.

To bypass prolonged delays within public services, some patients explore private pathways. Private providers offer adult screening, diagnostic assessment, treatment planning, and medication titration under consultant psychiatric care. For instance, IamPsychiatry provides titration services for individuals who already hold a diagnosis from another provider, reducing the need for duplicate assessments. Such private titration and stabilisation typically span several months, with pricing structures varying by urgency and initial assessment requirements, alongside potential additional costs for prescriptions, follow-up appointments, and pharmacy fees.

Once medication has been successfully titrated and stabilized, patients sometimes seek to transfer ongoing prescribing back to primary care via a shared-care agreement. However, acceptance of these arrangements remains entirely at the discretion of individual general practitioners, requiring patients to verify local surgery requirements ahead of time. Experts emphasize that comprehensive care must also incorporate psychosocial interventions and non-medication support, aligning with NHS recommendations to avoid treating medication as the sole form of assistance.

The wider crisis in service waiting times extends far beyond adult neurodiversity clinics, impacting routine treatments and emergency care across the UK health system. In Wales, performance data published by Going Private UK illustrates acute pressures, with hundreds of thousands of patient pathways waiting to start treatment amid consecutive monthly increases.

The stark contrast in waiting times highlights deep structural differences in how healthcare is managed and measured across different jurisdictions. While England utilizes an 18-week standard from referral to treatment, Wales measures performance against a 26-week standard, making direct statistical comparisons complex. Furthermore, patients registered with a Welsh general practitioner do not possess the same legal right to choose their hospital as patients in England, compounding frustrations for those caught in lengthy queues.

Patients experiencing worsening symptoms while waiting for care are consistently advised to contact their primary care physician or local health services for priority reviews. Meanwhile, regulatory bodies and healthcare providers continue to monitor the interplay between public backlogs and the growing reliance on private mental health clinics and independent medical insurance options.

What to Watch Next

• Future updates from NHS England regarding the implementation of recommendations put forward by the ADHD Taskforce.
• Upcoming monthly statistical releases on Welsh healthcare performance tracking patient pathways and treatment backlogs.
• Potential policy shifts concerning shared-care agreements between private psychiatric clinics and primary care general practices.